论文部分内容阅读
摘要目的探讨2D或3D Choi和改良的Choi(m Choi)标准评估依维莫司治疗转移性肾细胞癌疗效的价值。方法根据实体瘤疗效评价标准1.1,采用Choi和m Choi标准回顾性分析48例转移性肾细胞癌病人的基线和2个月CT增强影像,这48例病人入组法国的随机、双盲、多中心临床Ⅲ期依维莫司和安慰剂对比研究(RECORD-1)。本研究的主要目标是集中检验由最初的(RECORD-1)分析的无进展生存期
Abstract Objective To evaluate the value of everolimus in the treatment of metastatic renal cell carcinoma (NPC) with 2D or 3D Choi and modified Choi (m Choi) criteria. Methods The baseline and 2-month CT images of 48 patients with metastatic renal cell carcinoma were retrospectively analyzed using the Choi and m Choi criteria according to the criteria 1.1 of the solid tumor evaluation. These 48 patients were enrolled in the randomized, double-blind, Central Clinical Phase III Everolimus vs. Placebo (RECORD-1). The main goal of this study was to focus on the progression-free survival of the patients analyzed by the initial (RECORD-1)